Biomarker ID 2500 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2500 |
| Biomarker | RYBP, ATP1B3, TMC, ZNF567, GPR108, CD19, SPINK1, CDC2L6, RSRC1, METAP, GPC3, SNHG11, RY1, CRELD2, GLUL, SERPINB1, TRMT6, UNC13D, E4F1--E4F, SLC22A2, CNIH4, TK1, MAFB, PPP1CB, DNTTIP2, ARID4B, SMARCC2, PRO1386, TRIOBP, VARS, ITGA5, TERF1, PURA, TUBA1B, SNRPE, RRAGD, VWF, GLRX3, ILF2, |
| Biomarker Name/Symbol (given in Publication) | 40 genes-signature (RYBP, ATP1B3, TMC, ZNF567, GPR108, CD19, SPINK1, CDC2L6, RSRC1, METAP, GPC3, SNHG11, RY1, CRELD2, GLUL, SERPINB1, TRMT6, UNC13D, E4F1--E4F, SLC22A2, CNIH4, TK1, MAFB, PPP1CB, DNTTIP2, ARID4B, SMARCC2, PRO1386, TRIOBP, VARS, ITGA5, TERF1, PURA, TUBA1B, SNRPE, RRAGD, VWF, GLRX3, ILF2) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential biomarkers for diagnosis of HCV-related HCC; but not validated on independent dataset |
| Experimental Condition | HCV related HCC v/s normal control |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCV related HCC than normal control (With 3-fold change) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 19821982 |
| Type of Biomarker | Diagnostic |
| Pathway | Metabolism, Aryl Hydrocarbon receptor signaling, 14-3-3 mediated signaling and protein Ubiquitination pathways. |
| Cohort | 14 HCV-related HCC and non-HCC counterpart, as well as 7 HCV-negative control patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV-associated HCC |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |